Biota HoldingsBiota Holdings


Recent Highlights

Latest Articles

4 days, 14 hours ago

Biota Holdings targeting asthma market with flu drug spacer

Biota Holdings today commenced a 400-member trial in the US of its anti-viral drug BTA798 on sufferers of asthma who have contracted cold and flu. Life Scientist - 6:45 p.m. Tuesday 27th July 2010 EST View Article Related Articles Email to Friend

Also reported by:

5 days, 15 hours ago

Biota begins Phase 2 BTA798 flu study spacer

Biota begins Phase 2 BTA798 flu study... 26 Jul 2010 18:01 PM Business Spectator health & pharmaceuticals - 6:01 p.m. Monday 26th July 2010 EST View Article Related Articles Email to Friend

Also reported by:

1 week, 2 days ago

Australia, New Zealand Stocks: BHP, Biota, Downer, Qantas Airways, Vector spacer

By Lisa Pham and Shani Raja - Jul 22, 2010 Australia's S&P/ASX 200 Index lost 0.9 percent to 4,374.70 at the 4:10 pm close of trading in Sydney. New Zealand's ... Bloomberg - 11:19 a.m. Thursday 22nd July 2010 EST View Article Related Articles Email to Friend

Biota's Relenza royalty $900,000 spacer

Biota's Relenza royalty $900,000... 22 Jul 2010 10:40 AM Business Spectator health & pharmaceuticals - 10:40 a.m. Thursday 22nd July 2010 EST View Article Related Articles Email to Friend

Flu drug maker feeling a little poorly spacer

LONG-SUFFERING Biota holders today will wake up to news that royalties from the Relenza flu drug tanked in the fourth quarter. The Australian - Business - 2:57 a.m. Thursday 22nd July 2010 EST View Article Related Articles Email to Friend

3 weeks, 2 days ago

Biota Holdings issues 34k shares spacer

Biota Holdings issues 34k shares... 08 Jul 2010 11:21 AM Business Spectator health & pharmaceuticals - 11:21 a.m. Thursday 8th July 2010 EST View Article Related Articles Email to Friend

2 months, 1 week ago

AWB Limited (AWB) Profitability Ratios spacer

Rohan asked about AWB. The ratios for this business are lousy as the chart blow shows. Past management indiscretions, poor governance, hemorrhaging cash and the lousy business make this an ... Fusion Investing & Analysis - 9:38 p.m. Wednesday 19th May 2010 EST View Article Related Articles Email to Friend

2 months, 3 weeks ago

The ASX200 Losers of the Week spacer

Biota Holdings ( BTA ), one of the renowned companies in the anti-infective drug manufacturing industry was the worst performer in the ASX200 list for the 15th week. The company ... My Share Trading - 2:46 p.m. Tuesday 11th May 2010 EST View Article Related Articles Email to Friend

2 months, 3 weeks ago

Falling Knife: Biota Holdings Ltd. (BTA) spacer

Speaking of falling knives how about Biota? This Melbourne based anti-viral company, or I should say small molecule biotech company since their European anti ineffective acquisitions, had a serious haircut ... Fusion Investing & Analysis - 7:31 a.m. Thursday 6th May 2010 EST View Article Related Articles Email to Friend

2 months, 3 weeks ago

Falling Knife: ELDERS LIMITED (ELD) spacer

Elders is hitting new low. As Justin said in the comments a buck now seems likely. First up the two year chart and then zooming in the last six months. ... Fusion Investing & Analysis - 6:09 p.m. Wednesday 5th May 2010 EST View Article Related Articles Email to Friend

3 months ago

April No Waste Land - BDI-40 Down 2.4%, Cathrx Up 73%, Biota Loses 35%; GSK 2009 Sales Up 30% To $1.9bn, Helped By Biota's Relenza; Federal, Queensland Governments Contract DSM Biologics; BPH's Cortical Dynamics Presents Anaesthesia Data; Genetic Technolo spacer

Although 24 of the Biotech Daily Top 40 Index (BDI-40) companies fell in April with only 12 climbing, April was not the cruellest month after all (TS Eliot). The BDI-40 ... Biotech Daily - 8:03 a.m. Monday 3rd May 2010 EST View Article Related Articles Email to Friend

3 months ago

Biota boss lashes out spacer

SHARES in biotech Biota lost almost a quarter of their value yesterday as investors reacted to lower than expected royalties for flu drug Relenza. Herald Sun - 9:22 a.m. Friday 30th April 2010 EST View Article Related Articles Email to Friend

Biota dives as flu sales tumble spacer

INVESTORS have deserted drug developer Biota, after global sales of its flu medication slowed significantly. The Australian Business News - midnight Friday 30th April 2010 EST View Article Related Articles Email to Friend

3 months ago

Biota shares plunge on Relenza slump spacer

Shares in Biota Holdings plunged more than 20 per cent to a nine month low, after the company reported a slump in royalties from its anti-flu drug Relenza. TheBull - 4:44 p.m. Thursday 29th April 2010 EST View Article Related Articles Email to Friend

Also reported by:
Sharemarket falls as Biota slumps spacer

THE Australian sharemarket was down almost one per cent by early afternoon on bank weakness and a large fall from Biota. The Australian Business News - 12:37 p.m. Thursday 29th April 2010 EST View Article Related Articles Email to Friend

497 articles match your search
123456...3334>

Related Organizations

Related People

Related Locations

Related Publishers

Company Profile

Biota Holdings Limited (Biota) is an Australia-based drug discovery and early stage clinical development company. Biota’s focus is on anti-infectives and has developed a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease, licensed to AstraZeneca and nucleoside analogues designed to treat hepatitis C virus (HCV) infections, licensed to Boehringer Ingelheim. The Company's neuraminidase inhibitor, zanamivir, is marketed by GlaxoSmithKline as Relenza. Its influenza diagnostic developments are marketed by Inverness Medical under the BioStar OIA FLU and BioStar OIA FLU A/B brands. On July 31, 2008, Biota announced the completion of the initial Phase II clinical study of its second generation, influenza treatment, CS-8958, in Japan. On August 11, 2008, the Company announced that its human rhinovirus (HRV) program had commenced initial dosing of its Phase IIa clinical evaluation.

Address: 10/585 Blackburn Road, NOTTING HILL, VIC, AUSTRALIA, 3168

Phone: +61 3 9915 3700
Fax: +61 3 9915 3702